Pulmonary lymphangioleiomyomatosis (LAM) is a poorly understood disorder characterized by abnormal smooth muscle (SM)-like, tuberin-minus cell proliferation leading to lung destruction and pseudocyst formation. Serum response factor (SRF) is a transcription factor that plays an essential role in the regulation of SM myogenesis and cell growth. We recently found that LAM lesions exhibit high SRF expression levels. Furthermore, our studies demonstrated that upregulation of SRF in normal lung fibroblasts stimulates production of key extracellular matrix (ECM)-degrading enzymes including several metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). On the contrary, their corresponding inhibitors, tissue inhibitor of metalloproteinases-3 (TIMP-3) and plasminogen activator inhibitor-1 (PAI-1) are downregulated, resulting in an enzymatic imbalance that favors ECM degradation. Immunohistochemistry and laser microcapture confirmed that this imbalance is also present in LAM lesions. Since SRF is in addition a well established mitogenic transcription factor we hypothesize that high SRF levels contribute to the pathogenesis of LAM by creating a pro-proteolytic imbalance that favors ECM degradation and LAM cell proliferation/survival. Hence, SRF downregulation should eliminate these deleterious features. Furthermore, we hypothesize that exogenous TIMP-3 should also correct the proteolvtic imbalance in a more direct manner. To address our hypotheses we developed unique LAM culture systems, including LAM cell primary cultures (identifying LAM cells based on two novel LAM cell markers), lung explant cultures, and LAM xenografts in SCID mice. Here we specifically propose: 1- To determine whether SRF downregulation will correct the pro-proteolytic imbalance in LAM cells. 2- To elucidate whether SRF downregulation will change LAM cell behavior with regards to ECM invasion and cell proliferation/ apoptosis. 3- To determine whether exogenous TIMP-3 will decrease the activity of MMPs and improve LAM cell behavior. Our hypotheses will also be tested on ELT-3, a tuberin-minus cell line, to integrate the proposed studies with existing research on LAM. We believe that the new knowledge obtained from these studies will help to better understand the pathogenesis of LAM and to devise novel therapeutic strategies to treat this disease. ? ?

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Peavy, Hannah H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
Schools of Medicine
United States
Zip Code
Davis, Jennifer M; Hyjek, Elizabeth; Husain, Aliya N et al. (2013) Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histochem Cytochem 61:580-90
Badri, Kameswara Rao; Gao, Ling; Hyjek, Elizabeth et al. (2013) Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 187:663-5
Badri, Kameswara Rao; Yue, Ming; Carretero, Oscar A et al. (2013) Blood pressure homeostasis is maintained by a P311-TGF-? axis. J Clin Invest 123:4502-12
Badri, Kameswara Rao; Zhou, Yuanxiang; Schuger, Lucia (2008) Embryological origin of airway smooth muscle. Proc Am Thorac Soc 5:4-10
Badri, Kameswara Rao; Zhou, Yuanxiang; Dhru, Urmil et al. (2008) Effects of the SANT domain of tension-induced/inhibited proteins (TIPs), novel partners of the histone acetyltransferase p300, on p300 activity and TIP-6-induced adipogenesis. Mol Cell Biol 28:6358-72
Shi, Jinghua; Badri, Kameswara Rao; Choudhury, Ranginee et al. (2006) P311-induced myofibroblasts exhibit ameboid-like migration through RalA activation. Exp Cell Res 312:3432-42